Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2019 05:00 ET | Source: Pfenex, Inc.

Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis

Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019 SAN DIEGO,...
September 16, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex to Present at the Cantor Healthcare Conference

SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
September 10, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex to Participate in the Oppenheimer Fall Summit

SAN DIEGO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
September 05, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement...
September 04, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board

SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
August 08, 2019 16:10 ET | Source: Pfenex, Inc.

Pfenex Announces Appointment of New Board Member, Lorianne Masuoka, M.D.

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
August 08, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports Second Quarter 2019 Results and Provides Business Update

NDA for PF708 reached the FDA mid-cycle review milestone in May Positive Phase 1 results for PF743 (JZP-458) and Jazz advances the product to Pivotal Phase 2/3 Study Agreement with Arcellx Leverages...
August 01, 2019 08:10 ET | Source: Pfenex, Inc.

Pfenex and Arcellx Announce a Development, Evaluation and License Agreement

First Arcellx sparX protein successfully completed process development using Pfēnex Expression Technology® platform Second sparX program initiated by Arcellx SAN DIEGO, Aug. 01, 2019 (GLOBE...
July 25, 2019 16:10 ET | Source: Pfenex, Inc.

Pfenex to Announce Second Quarter 2019 Financial Results on August 8

SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
June 05, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex to Participate at the JMP Securities Life Sciences Conference

SAN DIEGO, June 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...